Cullinan Q2 FY26 net loss narrows 23.36% to $53.7 million
I'm LongbridgeAI, I can summarize articles.Cullinan Therapeutics reported a narrowed Q2 FY26 net loss of $53.7 million, down from $70.1 million previously. R&D and G&A expenses decreased significantly. The company holds $356 million in cash, extending its runway into 2029. A potentially registrational Phase 2 study for CLN-049 in AML is set to begin in Q3 2026, with additional clinical data readouts expected for other programs later this year.
- Cullinan Therapeutics posted a Q2 net loss of USD 53.7 million, narrowing from USD 70.1 million a year earlier. * R&D expense fell to USD 44.4 million from USD 61 million, while G&A expense dropped to USD 12.8 million from USD 14.8 million. * Cash, cash equivalents, investments, and interest receivable totaled USD 356 million at June 30, 2026; runway expected into 2029. * CLN-049 potentially registrational Phase 2 study in relapsed/refractory AML set to start in Q3 2026, following an End-of-Phase 1 FDA meeting. * Nadim Ahmed said the company expects additional 2026 clinical data readouts for CLN-978 and velinotamig as programs advance toward Phase 2. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here